Japanese pharmaceutical company Shionogi is sponsoring a drug that shows promise to kill antibiotic resistant bacteria. Increasingly, antibiotic resistant presents major challenges that modern healthcare continues to face. In many cases misuse or overuse of antibiotics intensifies the problems in populations worldwide. There are many crises points around the globe due to superbugs—and researchers are furiously attempting to find answers. Shionogi is sponsoring a phase 2 randomized trial with a goal of eradicating the superbug crisis. The results, reported in The Lancet Infectious Diseases (link below) introduce a new antibiotic effective in treating complicated urinary tract infections (UTIs) that are caused by stubborn Gran-negative bacteria, which are resistant to a series of other antibiotics.
The new drug, Cefiderocol—see https://en.wikipedia.org/wiki/Cefiderocol is an experimental parentally administered siderophorecephalosporin antibiotic aimed at countering multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. As of 2018, a phase 2 clinical trial appears to show efficacy similar to or better than imipenem-cilastatin in combating drug-resistant bacteria, and its makers, Shionogi Inc., have stated that they will seek approval for sale and marketing of the drug in a New Drug Application to the U.S. Food and Drug Administration.
It has been described in the popular press as a “Trojan-horse antibiotic” for its mechanism of entering bacterial cells by binding to iron, which is actively transported into the bacterial cells alongSource: The Lancet